Many pharmaceutical professionals still face an important question during Bioequivalence (BE) study planning:
How to Calculate Batch Size for Bio-Batch 10× Strategy?
Simple Explanation in KG and Units | EU, USFDA & SFDA Perspective
In pharmaceutical development, determining the bio-batch size is a critical step before conducting a BE study. A widely applied approach is the 10× rule, which ensures the batch used in BE studies accurately represents the commercial manufacturing process.
What is the 10X Strategy?
Regulatory agencies require that the batch used in the BE study reflects the final commercial manufacturing process.
A commonly accepted approach is that the bio-batch should be at least 10% of the proposed commercial batch size.
Regulatory Expectations
- EU regulators: At least 10% of the commercial batch size or 100,000 units, whichever is higher
- USFDA: Minimum 10% of the commercial batch or 100,000 units for solid oral dosage forms
- SFDA: Similar expectations aligned with international regulatory standards
This ensures that manufacturing during BE studies closely resembles commercial production conditions.
Simple Example (Tablet Product)
Proposed Commercial Batch Size: 1,000,000 tablets
Minimum Bio-Batch Requirement (10%): 100,000 tablets
Therefore, the BE study should ideally use tablets manufactured from a batch of ≥100,000 units.
Example in Kilograms
Tablet weight: 500 mg
Commercial Batch:
1,000,000 tablets × 500 mg = 500,000,000 mg = 500 kg
Bio-Batch (10%): 50 kg
Equivalent Units:
50 kg ÷ 500 mg per tablet = 100,000 tablets
Why Regulators Emphasize This
- Ensures manufacturing process scalability
- Confirms process reproducibility
- Reduces risk during commercial-scale production
- Demonstrates product quality consistency
Key Message
The 10X strategy is not just a calculation.
It is a regulatory expectation that bridges development scale and commercial manufacturing, ensuring the BE batch truly represents the marketed product.
For Regulatory Affairs, R&D, and Manufacturing teams, understanding this concept early can prevent major delays during dossier submission.
Read also: Batch Yield Calculation in Pharmaceutical Production
Resource Person: Kaunain Kareem Khan
Post a Comment